Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Neurocrine Biosciences
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07105111CT.gov A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | — | Recruiting | — | — | — |
NCT05859698CT.gov Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| MT-5199 (this asset) | Neurocrine Biosciences | Approved | B · 62 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Sertraline | University of Texas Southwestern Medical Center | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for MT-5199
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tardive Dyskinesia | — | P4 | BBB · 75 |
| Schizoaffective Disorder | — | P4 | BB · 68 |
| Huntington Disease | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. MT-5199 in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mt-5199-bipolar-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →